ZESTAGEN
Zestagen is a Swiss biotechnology company developing light chain mAbs against Extracellular Heat Shock Protein-90 (ehsp90). hsp90 is a validated pharmaceutical target. ehsp90 is implicated in cancer cell motility, migration and metastasis. It is detectable at the surface of several cancer cells but not of normal adult cells. Zestagen's mAbs bind ehsp90 at the surface of cancer cells (but not normal cells) leading to significant inhibition of metastasis in preclinical cancer animal models. Unlike small molecule hsp90 inhibitors which do not discriminate between the extracellular and intracellular hsp90 pool, Zestagen’s mAbs are predicted to display a superior therapeutic index in cancer patients.
ZESTAGEN
Industry:
Biotechnology Health Diagnostics Pharmaceutical
Founded:
2011-01-01
Address:
Epalinges, Vaud, Switzerland
Country:
Switzerland
Website Url:
http://www.zestagen.com
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Nginx GoDaddy DNS Peg Technic
Similar Organizations
Gendiag
gen to A monster is a biotechnological research and development company, founded in 2006 to facilitate personalized medicine.
Official Site Inspections
http://www.zestagen.com
- Host name: ec2-13-223-25-84.compute-1.amazonaws.com
- IP address: 13.223.25.84
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
